Pro-Dex, Inc. Announces Fiscal 2016 Third Quarter and Nine-Month Results
/EINPresswire.com/ -- IRVINE, CA -- (Marketwired) -- 05/12/16 -- PRO-DEX, INC. (NASDAQ: PDEX) today announced financial results for its fiscal 2016 third quarter ended March 31, 2016. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2016 with the Securities and Exchange Commission today.
Quarter Ended March 31, 2016
Net sales for the three months ended March 31, 2016 increased $1.4 million, or 36%, to $5.3 million from $3.9 million for the three months ended March 31, 2015, due primarily to increases in medical device revenues as well as an additional medical device product launch during the second quarter of fiscal 2016. Gross profit for the three months ended March 31, 2016 increased $315,000, or 30%, to $1.4 million from $1.1 million for the same period in fiscal 2015, primarily as a result of the increase in sales volume, described above.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended March 31, 2016 decreased $125,000 or 9% to $1.3 million compared to the prior fiscal year's corresponding quarter. During the quarter ended March 31, 2016 we recorded an impairment charge in the amount of $245,000 relating to Fineline Molds goodwill and intangible assets, as a result of our annual impairment test. This impairment charge, included in operating expenses, is offset by reduced legal and professional fees in the current fiscal year in the amount of $172,000 recorded in general and administrative expenses and a reduction in personnel and related costs primarily of our Engineering Services Division in the amount of $168,000.
Income from continuing operations for the quarter ended March 31, 2016 increased by $460,000 to $368,000, compared to a loss from continuing operations of $92,000 in the corresponding quarter in fiscal 2015. Net income for the quarter ended March 31, 2016 was $368,000, or $0.09 per share, compared to a net loss of $76,000, or $0.02 per share, for the corresponding quarter in fiscal 2015.
Nine Months Ended March 31, 2016
Net sales for the nine months ended March 31, 2016 increased $5.5 million, or 60%, to $14.9 million from $9.3 million for the nine months ended March 31, 2015, due primarily to increases in medical device revenues, which represents approximately 71% of our revenue for the nine months ended March 31, 2016.
Gross profit for the nine months ended March 31, 2016 increased $1.4 million, or 54% compared to the same period in fiscal 2015, primarily as a result of the increase in sales volume, described above.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the nine months ended March 31, 2016 increased 2% to $3.6 million from $3.5 million in the prior fiscal year's corresponding period, reflecting primarily the goodwill and long-lived asset impairment charge relating to our Fineline Molds division, a business we acquired in the third quarter of fiscal 2015.
Income from continuing operations for the nine months ended March 31, 2016 was $633,000, compared to a loss from continuing operations of $475,000 for the corresponding period in fiscal 2015. Net income for the nine months ended March 31, 2016 was $633,000, or $0.15 per share, compared to a net loss of $438,000, or $0.10 per share, for the corresponding period in fiscal 2015.
CEO Comments
Richard L. ("Rick") Van Kirk, the Company's President and Chief Executive Officer, commented, "We are pleased with our continued positive sales growth and have continued our earnings momentum with two consecutive quarters of profitability and I want to thank the Pro-Dex team as our results are reflective of their efforts. In addition, our gain on the Ramsey property is indicative of Pro-Dex's willingness to be open minded and flexible while looking for opportunities to increase shareholder value," continued Mr. Van Kirk.
"Although we recorded an impairment charge related to our Fineline Molds business, we gained valuable insight related to business acquisitions and integration and have made management changes that we believe will positively impact the division going forward. In the near term, however, we will be focusing our efforts on organic sales growth. Finally," concluded Mr. Van Kirk, "during the third quarter, the USPTO issued a long awaited patent, which we use in several of our medical device products, and protects one of our key technologies, which we believe has the potential to be used in many diverse applications. We also have a number of significant proposals outstanding with customers for new projects and in fact believe that we are close to finalizing terms on a new engineering project for our medical device core business. This business development activity has us encouraged about further growth for our core business as we take this turn around to the next level."
About Pro-Dex, Inc.:
Pro-Dex, Inc., with operations in California and Oregon, specializes in the design, development and manufacture of powered rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets. Its OMS division designs and manufactures embedded motion control systems serving the medical, factory automation, semi-conductor and scientific research markets. Its Fineline Molds division manufactures plastic injection molding for a variety of industries. Pro-Dex's products are found in hospitals, dental offices, medical engineering labs, scientific research facilities and high tech manufacturing operations around the world.
Pro-Dex also provides quality and regulatory consulting services, as well as engineering consulting and placement services through its Engineering Services Division. For more information, visit the Company's website at www.pro-dex.com.
Statements herein concerning the Company's plans, growth and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.
(tables follow)
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share amounts)
March 31, June 30,
2016 2015
---------- ----------
ASSETS
Current Assets:
Cash and cash equivalents $ 1,452 $ 697
Accounts receivable, net of allowance for
doubtful accounts of $18 and $36, respectively 2,169 2,326
Due from factor 1,581 --
Unbilled receivables 123 853
Other current receivables 113 28
Inventory 4,118 4,310
Prepaid expenses 129 124
Deferred income taxes -- 70
---------- ----------
Total current assets 9,685 8,408
Equipment and leasehold improvements, net 1,198 1,470
Investment in Ramsey property and related notes
receivable -- 1,652
Goodwill 112 353
Intangibles 442 547
Other assets 80 86
---------- ----------
Total assets $ 11,517 $ 12,516
========== ==========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts payable $ 1,132 $ 1,867
Accrued expenses 892 1,202
Deferred revenue 117 594
Income taxes payable 3 --
Note payable 24 24
Capital lease obligations -- 7
---------- ----------
Total current liabilities 2,168 3,694
---------- ----------
Deferred income taxes -- 70
Deferred rent 157 204
Note payable, net of current portion 52 70
---------- ----------
Total non-current liabilities 209 344
---------- ----------
Total liabilities 2,377 4,038
---------- ----------
Shareholders' equity:
Common shares; no par value; 50,000,000 shares
authorized; 4,152,139 and 4,139,579 shares
issued and outstanding at March 31, 2016 and
June 30, 2015, respectively 18,440 18,411
Accumulated deficit (9,300) (9,933)
---------- ----------
Total shareholders' equity 9,140 8,478
---------- ----------
Total liabilities and shareholders' equity $ 11,517 $ 12,516
========== ==========
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share amounts)
Three Months Ended Nine Months Ended
March 31, March 31,
-------------------- --------------------
2016 2015 2016 2015
--------- --------- --------- ---------
Net sales $ 5,337 $ 3,922 $ 14,873 $ 9,310
Cost of sales 3,977 2,877 10,916 6,741
--------- --------- --------- ---------
Gross profit 1,360 1,045 3,957 2,569
--------- --------- --------- ---------
Operating expenses:
Selling expenses 195 363 665 691
General and administrative
expenses 420 592 1,407 1,542
Impairment of goodwill and long-
lived assets 245 -- 245 --
Research and development costs 450 480 1,313 1,309
--------- --------- --------- ---------
Total operating expenses 1,310 1,435 3,630 3,542
--------- --------- --------- ---------
Operating income (loss) 50 (390) 327 (973)
Interest expense (10) (1) (36) (4)
Interest income -- 1 -- 6
Gain from sale of Investment in
Ramsey Property 340 -- 340 --
Gain from disposal of equipment 4 1 18 1
Realized gain on sale of
investments -- 395 -- 455
--------- --------- --------- ---------
Income (loss) from continuing
operations before income taxes 384 6 649 (515)
Income tax (expense) benefit (16) (98) (16) 40
--------- --------- --------- ---------
Income (loss) from continuing
operations 368 (92) 633 (475)
Income from discontinued
operations, net of income taxes -- 16 -- 37
--------- --------- --------- ---------
Net income (loss) $ 368 $ (76) $ 633 $ (438)
========= ========= ========= =========
Basic and diluted net income
(loss) per share:
Income (loss) from continuing
operations $ 0.09 $ (0.02) $ 0.15 $ (0.11)
Income from discontinued
operations -- -- -- 0.01
--------- --------- --------- ---------
Net income (loss) $ 0.09 $ (0.02) $ 0.15 $ (0.10)
========= ========= ========= =========
Weighted average common shares
outstanding:
Basic 4,151 4,158 4,145 4,179
Diluted 4,195 4,158 4,169 4,179
Common shares outstanding 4,152 4,140 4,152 4,140
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
Nine Months Ended
March 31,
----------------------
2016 2015
---------- ----------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $ 633 $ (438)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization 481 398
Gain on sale of investments -- (455)
Gain on sale of investment in Ramsey (340) --
Gain on disposal of equipment (18) (1)
Impairment of goodwill and long-lived assets 245 --
Share-based compensation 4 14
Deferred income tax benefit -- 5
Bad debt expense (recovery) (18) 1
Changes in operating assets and liabilities:
Accounts receivable, due from factor and other
current receivables (1,382) (313)
Unbilled receivables 730 (324)
Inventory 192 (839)
Prepaid expenses and other assets -- (83)
Accounts payable, accrued expenses and deferred
rent (1,092) 1,352
Deferred revenue (477) 298
Income taxes payable 3 (53)
---------- ----------
Net cash used in operating activities (1,039) (438)
---------- ----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of investments -- (12)
Purchases of equipment and leasehold improvements (106) (242)
Business acquisitions -- (865)
Purchase of notes receivable -- (1,236)
Purchase of Investment in Ramsey property and
related notes receivable (87) --
Proceeds from sale of investment in Ramsey 1,970 --
Proceeds from sale of equipment 18 1
Proceeds from sale of investments -- 1,324
Increase in intangibles (1) (50)
---------- ----------
Net cash provided by (used in) investing activities 1,794 (1,080)
---------- ----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Purchase of common stock (2) (154)
Proceeds from exercise of stock options and ESPP
contributions 27 --
Repurchase of stock options -- (32)
Borrowings from Summit loan 2,050 --
Repayments on Summit loan (2,050) --
Payments made for common stock rights offering -- (3)
Proceeds from note payable 500
Principal payments on notes payable and capital
lease (525) (6)
---------- ----------
Net cash used in financing activities -- (195)
---------- ----------
Net increase (decrease) in cash and cash equivalents 755 (1,713)
Cash and cash equivalents, beginning of period 697 3,188
---------- ----------
Cash and cash equivalents, end of period $ 1,452 $ 1,475
========== ==========
Contact:
Richard L. Van Kirk
Chief Executive Officer
(949) 769-3200
